Imalux seeks to confirm OTC's (Optical coherence tomography) value in major EU bladder cancer trials:
This article was originally published in Clinica
Executive Summary
Optical coherence tomography (OCT) manufacturer Imalux has begun a series of European bladder cancer trials to support its technology's value in identifying the earliest signs of the disease. One German study, which will involve over 25,000 patients, will also assess the technology's use in preventing tumour recurrence and progression. The Cleveland, Ohio firm's Niris OTC imaging system, which is already cleared for sale in the US and Europe, will be used in the studies. According to the company, the "application of the proven OCT technology is on the verge of becoming the sixth major imaging modality".
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.